May 03, 2023 Press Release for Alnylam
Alnylam Issues 2022 Corporate Responsibility Report
May 03, 2023
– Successfully Met Goals Outlined in MassBio’s Diversity, Equity, and Inclusion (DE&I) Industry Pledge –
– New Disclosures of Company’s Impact on Planet—Including Multiyear Data on Scope 1, Scope 2, and Select Scope 3
“Our dedication to ethical and responsible business practices is a key enabler for our long-term success,” said
Key highlights from the 2022 report include:
Met all Diversity, Equity, and Inclusion (DE&I) goals in MassBio’s Industry pledge.
U.S.supplier diversity program delivering on 2020 pledge to address inequity through six key areas: leadership and executive culture; inclusive company culture; recruitment; retention and development; accountability and sustainability; and supplier diversity.
Analyzed and published global multiyear data on Alnylam’s environmental impact.
Refined data collection process across scopes 1, 2, and select scope 3 GHG emissions to gather multiyear data and launched a new process to report water usage data for the first time.
Evolved approach to outreach and inclusion within clinical trials.
Trained clinical operations team, based in the
U.S.and Europe, on cultural competency frameworks to better serve communities who have traditionally been excluded from clinical trials, as well as set diversity goals for Alnylamtrials in common diseases.
Expanded Alnylam Challengers Health Equity
Initiative to Europe.
Partnered with innovative non-governmental organizations in the
UK, the Netherlands, and Italyto empower refugee populations to rebuild healthy, safe, and productive lives in their adopted homelands.
To learn more about corporate responsibility at
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005131/en/
(Investors and Media)
For Media Inquiries, please contact:
SVP, Investor Relations & Corporate Communications email@example.com 617-682-4340
For Investor Inquiries, please contact:
VP, Investor Relations & Corporate Communications firstname.lastname@example.org 617-551-8276
Essential assets and documents related to Alnylam